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Background - Alcohol septal ablation (ASA) is a standard treatment modality for Hypertrophic Obstructive Cardiomyopathy (HOCM). ASA also 
serves as a human model of an iatrogenic acute myocardial infarction (AMI), and the release patterns of the standard serum cardiac biomarkers are 
consistent following both an ASA and an AMI. Saliva has been previously shown to be a diagnostic fluid source for detecting biomarkers associated 
with cardiac injury, inflammation and risk of cardiovascular disease. Our goal was to correlate the kinetic release patterns of cardiac injury with both 
the standard cardiac biomarkers and biomarkers of inflammation in both serum and saliva following ASA for treatment of HOCM.
Methods - Serum and unstimulated whole saliva (UWS) analytes were measured in samples from ASA patients (n=15) collected at baseline and 
at 8, 16, 24 and 48 hours post-procedure. Samples were analyzed for 13 proteins relevant to cardiovascular disease using Beadlyte technology 
(Luminex®), ELISA, Regression analyses and ANOVA to determine the kinetic release patterns of each biomarker.
Results - Troponin I, Creatinine Kinase MB Fraction (CK-MB) and Myoglobin levels rose rapidly in serum and peaked at >800-fold, 175-fold, and 
10-fold, respectively, above baseline levels between 4 and 16 hours post-ASA (p<0.001). All 13 biomarkers were detectable in UWS, but only levels 
of Troponin I and C-reactive protein rose significantly during the postoperative course. UWS C-reactive protein levels increased 4.4-fold over baseline 
at 4 hours (p<0.05) and continued to rise to >12-fold by 48 hours post-ASA (p<0.05). UWS Troponin I rose 2-fold by 16 hours (p=0.1) and remained 
elevated longer in UWS than in serum (2.7-fold at 48 hours [p=0.009]). UWS CK-MB and Myoglobin demonstrated kinetic release patterns similar to 
serum.
Conclusion - Kinetic release patterns of serum cardiac biomarkers correlate following both ASA and an AMI. Saliva reflects these patterns although 
only UWS Troponin I and C-reactive protein are significantly elevated above baseline levels. These data suggest that a saliva-based test may be 
useful for providing important screening diagnostic information relevant to cardiac injury following an AMI.
